Ravi Viswanathan's Net Worth

$15.3 Thousand

Who is Ravi Viswanathan?

Ravi Viswanathan does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include RHYTHM PHARMACEUTICALS, INC., Cascadian Therapeutics, Inc., Workday, Inc., Care.com Inc, Millennial Media Inc., AEROHIVE NETWORKS, INC, MULESOFT, INC, Elastic N.V., AVEO PHARMACEUTICALS INC, APPIAN CORP, Mersana Therapeutics, Inc., Clovis Oncology, Inc., Adaptimmune Therapeutics PLC, Duolingo, Inc., BOX INC, Loxo Oncology, Inc., Dermira, Inc., CHAMPIONS ONCOLOGY, INC., Surface Oncology, Inc., GENOCEA BIOSCIENCES, INC., PhaseBio Pharmaceuticals Inc, TESARO, Inc., ARDELYX, INC., GLYCOMIMETICS INC, Tracon Pharmaceuticals, Inc., Mirna Therapeutics, Inc., Epizyme, Inc., Arsanis, Inc., Cerecor Inc., Roka BioScience, Inc., Regulus Therapeutics Inc., ARCA biopharma, Inc., Marker Therapeutics, Inc., Omthera Pharmaceuticals, Inc., Ra Pharmaceuticals, Inc., Strongbridge Biopharma plc, CVENT INC, Achaogen Inc, and INTERLEUKIN GENETICS INC.

SEC CIK

Ravi Viswanathan's CIK is 0001479386

Past Insider Trading and Trends

2018 was Ravi Viswanathan's most active year for acquiring shares with 1 total transactions. Ravi Viswanathan's most active month to acquire stocks was the month of January. 2018 saw Ravi Viswanathan paying a total of $0.00 for 509 shares, this is the most they've acquired in one year.